Topic summary

About the Other compounds category

Compounds › Other compounds research use only custom synthesis needs a source Pinned Wiki Closed

This is a generated summary. It shows the 5 most-liked posts from a topic of 13, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

KLindqvistTL4 Moderator14 Dec 2025#1

Community wiki post. Any member at trust level 3 or above can edit this post; every edit is recorded. Last edited by hana.sato on 20 Mar 2026.

23 Feb 2026 — KLindqvist: Removed a claim that the cited source did not support.
12 Jun 2026 — mira.patel: Replaced an unsourced figure with the published one and cited it.
20 Mar 2026 — hana.sato: Added the worked example and a unit label to the table header.

Editors: KLindqvist, mira.patel, hana.sato

Staff post. Actions described here are recorded in the public moderation log and may be challenged in Meta.

Anything not covered by a dedicated subcategory, including research-use-only material with no human data.

This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a note. If the scope described here has drifted from what actually gets posted, edit it rather than starting a topic about it.

What belongs here

Questions specific to other compounds, with the units and the context stated.
Reports and datasets, with the collection method stated.
Disagreement about the substance, conducted in public.

What belongs elsewhere

Anything urgent belongs in Safety, immediately, and not here.
Anything about how this site works belongs in Meta.
Requests for a maintained page belong in Wiki requests.

Before posting, it is worth checking the documentation commons and this category's tag pages. A great deal of what gets asked here has a maintained answer with a review date on it, which is more reliable than a two-year-old reply.

33 likes 7mo

KTurkingtonTL3Regular19 Dec 2025 · edited#5

m.yilmaz, post #3: As a member rather than staff: the most useful thing I did when I started reading this category was to work through the tag pages rather than the topic list. The topic list shows you what is recent. The tags show you what is settled. Go to post

AOD-9604 is a fragment of human growth hormone and has been discussed as a potential weight-loss agent based on theoretical mechanism. The fragment hypothesis — that the fragment retains a specific property of the intact hormone — is not settled for this compound.

24 likes in reply to #3 7mo

a.friskTL2 Moderator22 Dec 2025#8

s.duarte, post #4: Suggestion for the wiki post above: it would be worth linking the two or three most-referenced topics in this category directly, since new members reliably ask for exactly those. Happy to make the edit myself if nobody objects, with a revision note. Go to post

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

11 likes in reply to #4 7mo

buffer_reviewTL3Regular23 Dec 2025#9

post #8 answers the question as asked. The question underneath it is different.

Naming conventions for research peptides cause confusion because suppliers do not follow a standard. The same compound gets different names from different suppliers. If you are researching something, confirming the sequence or mass is more reliable than confirming the name.

32 likes 7mo

t.waldenstrmTL2Member24 Dec 2025#11

Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits stated as established benefits — all of that is marketing. Treat it as such and separate it from evidence where evidence exists.

22 likes 7mo

Read the full topic (13 posts)

This topic was referenced in

Research-use-only status: what it means legally and practicallyCompounds › Other compounds · 81 replies

This topic was closed 30 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

Topic	Participants	Replies	Views	Activity
AOD-9604 and the fragment hypothesis, revisited — does this still hold? Compounds › Other compounds research use only needs a source mislabelling Solved The question in the title: AOD-9604 and the fragment hypothesis, revisited — does this still hold? I will give what I have already checked below so nobody repeats it. Comparing FLOW ( N Engl J Med , 2024)…	+7	11	31k	19h
Coming back to: Reading a supplier's product description as a marketing document Compounds › Other compounds needs a source custom synthesis research use only mislabelling Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…	+35	39	688	5mo
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Compounds › Other compounds custom synthesis mislabelling research use only Solved Posting this under the heading it deserves: Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Everything below is what sits behind that. Comparing SURMOUNT-4 ( JAMA , 2024) with…	+119	141	22k	20mo
Sequence verification for an obscure compound: how it is done — what changed since Compounds › Other compounds custom synthesis needs a source mislabelling On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please…	+100	108	1.3k	8mo
Melanocortin agonists: mechanism and the documented adverse profile Compounds › Other compounds needs a source mislabelling research use only custom synthesis Melanocortin agonists: mechanism and the documented adverse profile — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-2 ( Lancet , 2023) and…	+7	11	5.5k	20mo

Related topics — sharing the tags research use only, custom synthesis, needs a source

Topic	Participants	Replies	Views	Activity
Prescription requirements and telehealth models — a second dataset Sourcing › Regulatory compounding EMA MHRA personal import On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. A logistics question, since the answers here are usually better than…	+87	94	1.1k	21d
Warfarin and altered intake: the monitoring argument Practice › Interactions hypoglycaemia needs a source insulin Solved Warfarin and altered intake: the monitoring argument — setting out what I have, and where I think it stops being reliable. I have read the maintained page on this and I still have a gap, so I am asking rather…		2	11k	4mo
A payment that went through twice: how it was resolved Sourcing › Payments payments research use only documentation quality Solved Closed A payment that went through twice: how it was resolved Writing it up because I had to work it out twice and would rather nobody else did. I would like to talk about documentation quality as a signal,…	+20	24	55k	3mo
Compounds this community declines to help with, and why — does this still hold? Compounds › Other compounds custom synthesis research use only mislabelling Compounds this community declines to help with, and why — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med ,…	+3	7	26k	7h
Revisiting: What a well-designed human trial of a secretagogue would look like Compounds › Secretagogues & GH axis CJC-1295 observational data needs a source GHRP class On the subject in the title: Revisiting: What a well-designed human trial of a secretagogue would look like Working notes rather than a conclusion. Session topic: SELECT ( N Engl J Med , 2023). Please read it…	+69	74	25k	18mo